FMP
RenovoRx, Inc.
RNXT
NASDAQ
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
1.24 USD
0.003 (0.241%)
About
ceo
Mr. Shaun R. Bagai
sector
Healthcare
industry
Biotechnology
website
https://renovorx.com
exchange
NASDAQ
Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
CIK
0001574094
ISIN
US75989R1077
CUSIP
75989R107
Address
4546 El Camino Real
Phone
650 284 4433
Country
US
Employee
8
IPO Date
Aug 26, 2021
Key Executives
